In Tandem3, a phase 3 double-blind clinical trial, the authors concluded that the proportion of patients with T1DM on insulin and who received sotagliflozin accomplished a HbA1c level of less than 7.0% (without severe hypoglycemia or diabetic ketoacidosis (DKA)) was larger than the placebo group. The gene discussed is INS; the disease is type 1 diabetes mellitus.